NASDAQ: BCPC

Balchem (BCPC) Stock Analysis & Forecast

Nov 13 close

$173.14+0.79 (+0.5%)

Gekko Brief

AI summaryNov 9 close

Balchem's week was shaped by a strong third-quarter report, with record net income of $46.7 million and revenue growth of 8.6%, alongside adjusted EBITDA up 12.5% to $80.3 million at a record 27.6% margin. The Human Nutrition & Health segment led results, posting 8% revenue growth and 11% higher operating income. The stock also touched a new 52-week high of $183.9, reflecting roughly 19.94% appreciation over the past year, and commentary noted a significant share repurchase alongside the quarterly results, with some views describing the stock as near fair value following its run and others flagging capacity utilization and market risks.

BCPC closed at $175.99, up 0.9%, sitting above both its 50-day average of $169.94 and 200-day average of $169.56, with the 50-day above the 200-day. The GekkoIndex reads 53.4, placing it in the Neutral zone. Shares trade 2.4% below Gekko Fair Value of $180.23, within the 52-week range of $152.42 to $186.15.

The next earnings date falls on 19 February 2027, 101 days out, placing it outside a typical 20-trading-day holding window. Over the last 90 days, Congressional activity shows 1 buy and 0 sells. Seasonality from this point in the calendar has averaged a 0.9% gain over the next 20 trading days across 4 years, rising in 2 of them. A single analyst carries a buy rating with a consensus target of $213.5, implying 21.3% upside from current levels.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Balchem price vs fair value

$175.56$173.14May ’25May ’26Nov ’26
Close $173.14200-day averageGekko Fair Value $175.56

Balchem quick facts

Market cap
$5.52B
P/E ratio
32.5
Forward P/E
29.6
EPS, TTM
$5.30
Revenue, TTM
$1.11B
Profit margin
15.4%
Dividend yield
0.55%
Beta
0.85
Volume
144,012 avg 291,852
1-year return
+5.0%
Typical daily move
±2.7%
Typical 20-day move
±4.7%
50-day average
$169.86
200-day average
$169.67
Next earnings
Feb 19
Shares outstanding
31.88M
52-week range
$152.42$186.15

Balchem swing-trade checklist

Balchem scores 3 supportive, 3 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive3 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $173.14 is above the 50-day ($169.86) and 200-day ($169.67) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    58.3, Neutral

    Reading 58.3 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    1.4% below

    Price is within 5% of Gekko Fair Value (1.4% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: Congress 1 buy / 0 sales.

    See smart money
  • Earnings risksupportive

    Reports in 96 days

    Next report Feb 19, 2027, 96 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +1.2% on average

    From this point in the calendar, the next 20 trading days averaged +1.2% over 4 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Balchem stock chart and price history

Balchem closed at $173.14 on Nov 13, 2026, +5.0% over the past year, inside a 52-week range of $152.42 to $186.15.

Close50-day average200-day averageVolume
Balchem share price, past year, with 50-day and 200-day moving averages and volume$160$170$180JunJulFebMarAprMayJunJulAugSepOctNov173.14

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+1.5%
3 months
−2.9%
6 months
+8.9%
1 year
+5.0%
The full BCPC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BCPC in Gekko

Follow Balchem through every session

Put BCPC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BCPC in GekkoFree for 7 days. No credit card required.

About Balchem

Balchem produces specialty ingredients that reach into food, pharmaceutical, animal care, medical sterilization, plant nutrition, and industrial uses around the world. Among its offerings are encapsulated nutrients, vitamin K2, choline-derived compounds, mineral chelates, and gases applied in sterilizing medical equipment, which together give the company recognition across several markets.

Its operations fall into three areas. One focuses on ingredients for food and drink makers, supplying items such as dried powders, lipid blends, flavor systems, and bases used in dairy, juice, chocolate, cereal, and ice cream production. Another serves animal health, offering nutrient delivery methods and absorption-enhancing chelation technology for livestock and pets alike. A third handles specialty distribution, moving ethylene oxide and ammonia for hospital sterilization work, fumigants that guard nuts, spices, cacao, and dried fruit from pests and spoilage, and mineral chelates for agricultural crops. Balchem reaches its customers directly and also relies on outside distributors and agents to move its goods to market.

Founded in 1967, the company keeps its headquarters in Montvale, New Jersey, and its stock is listed on the NASDAQ under the ticker BCPC.

Listed
NASDAQ
Sector
Consumer non-durables
Industry
Food: specialty/candy
Website
balchem.com

Balchem GekkoIndex: the smart money zone

Balchem’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.3, in the Neutral zone, up 5.9 points over five sessions.

010058.3Neutral

Up 5.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying29+1.0%+2.3%+3.8%+6.8%
Accumulation157+0.7%+1.3%+3.8%+3.0%
Neutral (current zone)3610.0%−0.1%−0.6%+0.5%
Distribution24+0.9%+0.7%−0.6%−1.0%
Selling4Too few readings yet

Average BCPC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the BCPC price, zone by zone.Track BCPC in Gekko

Is Balchem stock overvalued? Gekko Fair Value

Balchem trades 1.4% below Gekko Fair Value of $175.56, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Balchem shares are worth, recalculated every trading day.

$175.56

Gekko Fair Value, Nov 14, 2026

1.4% below fair value · About fair value

At the end of Aug 2026 the price was 4.1% below the estimate.

Gekko Fair ValueShare price, month end
$176$173Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BCPC in Gekko

Balchem insider and Congress trading

No open-market insider purchases were filed for Balchem, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BCPC in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BCPC insider filing, plotted on the chart in Gekko.Open BCPC in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Gilbert Cisneros
House, CA, purchase
Purchase$1,001 - $15,000Oct 12
traded Sep 17

From congressional disclosures, which report amounts as ranges.

Buybacks

Balchem has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$27.44M
As a share of market cap
0.50%
Trailing four quarters
$125.6M

From company filings.

Balchem earnings: next date and track record

Balchem reports on Feb 19, 2027 (96 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±1.8%average move across the report
7 of 8reports followed by a gain

Share-price move across each report

+3.9%Jul ’24+2.8%Oct ’24+1.8%Feb ’25+3.4%May ’25+0.4%Jul ’25+0.4%Oct ’25+1.1%Feb ’26−0.8%Apr ’26
ReportedEPSSurpriseRevenueSurpriseMove
Apr 24, 2026$1.33
est $1.24
+7.3%——−0.8%
Feb 13, 2026$1.31
est $1.18
+11.0%$263.6M
est $259.6M
+1.6%+1.1%
Oct 21, 2025$1.35
est $1.36
−0.7%$267.6M
est $259.6M
+3.1%+0.4%
Jul 24, 2025$1.27
est $1.11
+14.4%$255.5M
est $257.6M
−0.8%+0.4%
May 1, 2025$1.22
est $1.22
+0.4%$250.5M
est $245.7M
+2.0%+3.4%
Feb 14, 2025$1.13
est $1.11
+2.3%——+1.8%
Oct 25, 2024$1.13
est $1.11
+1.8%$239.9M
est $235.1M
+2.1%+2.8%
Jul 26, 2024$1.09
est $1.03
+5.8%$234.1M
est $239.7M
−2.3%+3.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Balchem stock forecast and analyst price targets

Analysts’ average 12-month price target for Balchem is $213.50, +23.3% from the last close, from 1 firm rating the stock in the last 90 days.

$213.50consensus 12-month target, +23.3% from the last close
Buy1
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 1 firm.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 26H.C. WainwrightBuy, reiterated$210+21.3%
−0.6%average 20-day move after past Neutral readings
+1.2%average move over the next 20 trading days in the last 4 years
±2.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Balchem seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Balchem averaged +1.2% across the last 4 years, rising in 2 of them.

Next 20 trading days, by year

+1.0%2021−7.3%2022+11.2%2023−0.6%2024

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.6%3 of 4
Next 10 trading days−1.6%1 of 4
Next 15 trading days−1.3%2 of 4
Next 20 trading days+1.2%2 of 4
Next 30 trading days+0.1%2 of 4

For scale, BCPC’s typical 20-trading-day move in either direction is about 4.7%.

Balchem market cap and key statistics

Balchem’s market cap is $5.52B, with a P/E ratio of 32.5 and revenue of $1.11B over the last twelve months.

Valuation

Market cap
$5.52B
P/E ratio
32.5
Forward P/E
29.6
EPS, TTM
$5.30
Gekko Fair Value
$175.56

Trading

Volume
144,012
Avg volume, 20 days
291,852
52-week high
$186.15
52-week low
$152.42
Shares outstanding
31.88M

Financials

Revenue, TTM
$1.11B
Profit margin
15.4%
Return on equity
13%
Quarterly earnings growth, YoY
+17.7%

Risk and income

Beta
0.85
Typical daily move
±2.7%
Typical 20-day move
±4.7%
Dividend yield
0.55%

Balchem stock news this week

1 headline about Balchem from the past week, newest first, each linking to the publisher.

Balchem peers

Balchem’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
PEPPepsiCo+1.9%Neutral3.2% below
MDLZMondelez International+1.0%Neutral17.4% below
HSYHershey−0.5%Neutral22.9% below
IFFInternational Flavors & Fragrances+0.2%Accumulation2.7% below
SJMJ.M. Smucker+0.8%Neutral16.6% above
MKCMcCormick−0.1%Accumulation15.7% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Food: specialty/candy

Balchem stock FAQ

What is Balchem’s market cap?

Balchem’s market cap is $5.52B at the Nov 13, 2026 close of $173.14, with 31.88M shares outstanding. The shares trade on a P/E ratio of 32.5.

What is the Balchem stock forecast?

The consensus analyst 12-month price target for Balchem is $213.50, +23.3% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Balchem stock overvalued or undervalued?

On Gekko’s estimate Balchem is about fair value: the Nov 13, 2026 close of $173.14 is 1.4% below Gekko Fair Value of $175.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Balchem report earnings next?

Balchem is expected to report on Feb 19, 2027 (96 days away). Analysts expect earnings of $1.41 per share on revenue of $286.9M. Balchem beat the earnings estimate in 7 of its last 8 reports, moving 1.8% on average across the report.

What is Balchem’s 52-week high and low?

Balchem’s 52-week high is $186.15 and its 52-week low is $152.42; it closed at $173.14 on Nov 13, 2026, +5.0% over the past year.

Is Balchem stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk), 3 as mixed (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Balchem the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.